Mark Sullivan
CIK 1331843 · Chief Legal Officer · last filed 2026-06-26
Mark Sullivan is a Chief Legal Officer who has filed 34 SEC Form 4 insider transactions across 4 companies since 2011. The most recent filing shows the insider sold $585.8K of DFTX on Jun 26, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $14.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$14.23M
4
34
-$1.55M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DFTX | Chief Legal Officer | 320,571 | $44.39 | $14.23M | -$783.4K | 4 | 2026-06-26 |
| Definium Therapeutics, Inc. (MNMD) Delisted | Chief Legal Officer | 282,576 | $15.00 | $4.24M | -$569.9K | 10 | 2025-12-29 |
| Carisma Therapeutics Inc. (SESN) Delisted | General Counsel & Secretary | 19,186 | $12.58 | $241.3K | -$152.1K | 6 | 2023-03-06 |
| MModal Inc. (MEDH) Delisted | Gen Counsel, CCO & Secretary | 39,268 | — | — | -$43.7K | 5 | 2012-01-04 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-26 | DFTX | Sell (S) | −13,008 | -$585.8K | EDGAR |
| 2026-06-25 | DFTX | Notice (144) | −13,008 | -$548.0K | EDGAR |
| 2026-06-22 | DFTX | Grant (A) | +62,500 | $0 | EDGAR |
| 2026-03-26 | DFTX | Sell (S) | −10,702 | -$197.7K | EDGAR |
| 2026-03-25 | DFTX | Notice (144) | −10,702 | -$197.7K | EDGAR |
| 2026-02-05 | DFTX | Grant (A) | +125,000 | $0 | EDGAR |
| 2025-12-29 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −11,276 | -$148.2K | EDGAR |
| 2025-12-29 | DFTX | Notice (144) | −11,276 | -$148.2K | EDGAR |
| 2025-09-26 | Definium Therapeutics, Inc. (MNMD) Delisted | Sell (S) | −11,278 | -$110.2K | EDGAR |
| 2025-09-25 | DFTX | Notice (144) | −11,278 | -$110.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.